Pharmacological Inhibition of Host Heme Oxygenase-1 Suppresses Mycobacterium tuberculosis Infection In Vivo by a Mechanism Dependent on T Lymphocytes.

Permalink
https://escholarship.org/uc/item/9b61f292

Journal
mBio, 7(5)

ISSN
2150-7511

Authors
Costa, Diego L
Namasivayam, Sivaranjani
Amaral, Eduardo P
et al.

Publication Date
2016-10-25

DOI
10.1128/mBio.01675-16

Peer reviewed
Pharmacological Inhibition of Host Heme Oxygenase-1 Suppresses *Mycobacterium tuberculosis* Infection *In Vivo* by a Mechanism Dependent on T Lymphocytes

Diego L. Costa,¹ Sivaranjani Namasivayam,¹ Eduardo P. Amaral,¹ Kriti Arora,² Alex Chao,³ Lara R. Mittereder,² Mamoudou Maiga,¹ Helena I. Boshoff,¹ Clifton E. Barry III,¹ Celia W. Goulding,⁵,⁶,⁷ Bruno B. Andrade,¹,⁶,⁷ Alan Sher¹

Immunobiology Section, Laboratory of Parasitic Diseases, NIAID, NIH, Bethesda, Maryland, USA; Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA; Department of Molecular Biology and Biochemistry, University of California, Irvine, Irvine, California, USA; Department of Pharmaceutical Sciences, University of California, Irvine, Irvine, California, USA; Unidade de Medicina Investigativa, Laboratório Integrado de Microbiologia e Imunorregulação, Instituto Pesquisas Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil; Multinational Organization Network Sponsoring Translational and Epidemiological Research, Instituto Brasileiro para a Investigação da Tuberculose, Fundação José Silveira, Salvador, Bahia, Brazil

**ABSTRACT**  Heme oxygenase-1 (HO-1) is a stress response antioxidant enzyme which catalyzes the degradation of heme released during inflammation. HO-1 expression is upregulated in both experimental and human *Mycobacterium tuberculosis* infection, and in patients it is a biomarker of active disease. Whether the enzyme plays a protective versus pathogenic role in tuberculosis has been the subject of debate. To address this controversy, we administered tin protoporphyrin IX (SnPPIX), a well-characterized HO-1 enzymatic inhibitor, to mice during acute *M. tuberculosis* infection. These SnPPIX-treated animals displayed a substantial reduction in pulmonary bacterial loads comparable to that achieved following conventional antibiotic therapy. Moreover, when administered adjunctively with antimycobacterial drugs, the HO-1 inhibitor markedly enhanced and accelerated pathogen clearance. Interestingly, both the pulmonary induction of HO-1 expression and the efficacy of SnPPIX treatment in reducing bacterial burden were dependent on the presence of host T lymphocytes. Although *M. tuberculosis* expresses its own heme-degrading enzyme, SnPPIX failed to inhibit its enzymatic activity or significantly restrict bacterial growth in liquid culture. Together, the above findings reveal mammalian HO-1 as a potential target for host-directed monotherapy and adjunctive therapy of tuberculosis and identify the immune response as a critical regulator of this function.

**IMPORTANCE**  There is no reliable vaccine against tuberculosis (TB), and conventional antibiotic therapy is administered over at least 6 months. This prolonged treatment period can lead to noncompliance resulting in relapsed infection as well as the emergence of multidrug resistance. Thus, there is an urgent need for improved therapeutic regimens that can more rapidly and efficiently control *M. tuberculosis* in infected patients. Here, we describe a potential strategy for treating TB based on pharmacological inhibition of the host heme-degrading enzyme HO-1. This approach results in significantly reduced bacterial burdens in mice, and when administered in conjunction with conventional antibiotic therapy, leads to faster, more effective pathogen clearance without detectable direct effects on the mycobacteria themselves. Interestingly, the effects of HO-1 inhibition on *M. tuberculosis* infection *in vivo* are dependent on the presence of an intact host immune system. These observations establish mammalian HO-1 as a potential target for host-directed therapy of TB.

*Mycobacterium tuberculosis* is now regarded as the world’s leading cause of death due to a single infectious agent. While effective chemotherapy exists for the treatment of tuberculosis (TB), the standard antibiotic regimens must be administered for a minimum of 6 months, and noncompliance can lead to disease reactivation together with the emergence of multidrug-resistant bacterial strains (1). In the absence of a reliable vaccine, the development of new therapeutic approaches that can more effectively and rapidly control *M. tuberculosis* are greatly needed to reduce the current global disease burden.

Host-directed therapy (HDT) has a unique advantage for achieving this goal in that, by targeting host factors that play crucial functions during the infectious process rather than targeting the pathogen itself, HDT should not promote the development of drug-resistant bacteria. In the case of TB, a number of different HDT approaches have been proposed or are in clinical trials, and
are being tested for their ability to accelerate conventional chemotherapy or treat multidrug-resistant infections (2).

In this study, we identify heme oxygenase-1 (HO-1) as a potential target for HDT of TB. This antioxidant enzyme, which catalyzes heme degradation into biliverdin, iron, and carbon monoxide (3), is induced during both experimental and clinical M. {\textit{tuberculosis}} infection, and its production is reduced following successful antibiotic treatment (4–7). Previous studies have shown that mice genetically deficient for HO-1 are more susceptible to M. {\textit{tuberculosis}} infection (8). However, the interpretation of the latter finding is complicated by the presence of prominent hematopoietic abnormalities in these animals (9, 10). Moreover, in sera from TB patients, HO-1 levels are positively rather than negatively correlated with disease severity (6). These observations led us to test the function of HO-1 on experimental TB by administering a widely utilized pharmacological inhibitor of the enzyme, tin protoporphyrin IX (SnPPiX), to M. {\textit{tuberculosis}}-infected C57BL/6 mice.

Methods. (i) Mice and M. {\textit{tuberculosis}} infections. C57BL6 and TCR-α−/− mice were purchased from Taconic Farms (Germantown, NY, USA). All animals were housed at biosafety level 2 (BSL-2) and BSL-3 animal facilities at the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), and all experiments utilized protocols approved by the NIAID Animal Care and Use Committee. Mice were infected with approximately 100 CU of the H37Rv strain of M. {\textit{tuberculosis}} by using an aerosol chamber (Glas Col, Terre Haute, IN, USA). Determination of bacterial loads was performed by culturing serial dilutions of tissue homogenates in 7H11 medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with oleic acid-albumin-dextrose-catalase (BD Biosciences, San Diego, CA, USA).

Additional information on the materials and methods used in our study can be found in Text S1 in the supplemental material.

(ii) Antibiotic and SnPPiX treatments. The antibiotics rifampin (R; 10 mg/kg of body weight/mouse), isoniazid (I; 25 mg/kg/mouse), and pyrazinamide (Z; 150 mg/kg/mouse) (all from Sigma-Aldrich) were used. M. {\textit{tuberculosis}}-infected mice were treated with a cocktail of RH during the first 60 days of treatment and with RH thereafter. The drugs were administered by gavage 5 days per week, and fresh stock solutions were prepared weekly. The heme oxygenase-1 inhibitor SnPPiX (Frontier Scientific, Logan, UT, USA) was administered by intraperitoneal injection (5 mg/kg/mouse). The drug was dissolved in 0.1 M NaOH aqueous solution and then diluted in 10× phosphate-buffered saline (PBS), with further pH adjustment to 7.0 to 7.4. Aliquots were frozen at −80°C and thawed immediately prior to inoculation.

(iii) Quantification of Hmox1 mRNA expression by real-time PCR. mRNA was extracted from lungs of M. {\textit{tuberculosis}}-infected and naïve mice by using Trizol reagent (Invitrogen/Thermo Fisher Scientific, Waltham, MA, USA), and RNasey minikits (Qiagen, Hilden, Germany). cDNA was reverse transcribed using 1 µg of RNA, SuperScript II reverse transcriptase, and random primers (all from Invitrogen/Thermo Fisher Scientific). SYBR green and 7900HT fast real-time PCR systems (Applied Biosystems/Thermo Fisher Scientific) were employed for real-time PCRs. The relative expression of HO-1 in M. {\textit{tuberculosis}}-infected mouse lungs was calculated using the ΔΔCT (cycle threshold) method, normalizing mRNA expression in each sample to that of β-actin, and further comparing them in relation to expression in uninfected naïve mouse lungs. The primer sequences used are provided in Table S2 in the supplemental material.

(iv) HO-1 measurement in lung homogenates by using Western blotting. Briefly, M. {\textit{tuberculosis}}-infected and naïve mouse lungs were perfused with PBS and homogenized in PBS containing Complete Ultra protease inhibitor cocktail (Roche, Basel, Switzerland) and 2 mM phenylmethanesulfonyl fluoride (Sigma Aldrich). The protein concentrations from all samples were normalized, and then reducing buffer (Pierce/Thermo Fisher Scientific) was added to samples prior to incubation for 5 min at 95°C for protein denaturation. Samples were separated in Mini-Protein TGX gels (Bio-Rad, Hercules, CA, USA) and transferred to polyvinylidene difluoride membranes prior to staining with anti-mouse HO-1 (SPA-895; Enzo Life Sciences, Farmingdale, NY, USA) or anti-mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH; ab9485; Abcam, Cambridge, MA, USA) and anti-rabbit IgG conjugated to horseradish peroxidase (catalog number 7074; Cell Signaling Technology, Danvers, MA, USA).

(v) Statistical analyses. Differences between groups were statistically evaluated by using an unpaired Student t test (based on a parametric distribution of the data) within Prism software (GraphPad, San Diego, CA, USA), and differences were considered significant when P was ≤0.05.

Findings. When given to animals by daily intraperitoneal injection beginning on the same day as aerosol M. {\textit{tuberculosis}} infection (Fig. 1A, protocol 1), SnPPiX induced a highly significant reduction in pulmonary bacterial load that was evident at 6 weeks but not 3 weeks postinfection (wpi) (Fig. 1B). A similar reduction was achieved when SnPPiX treatment was initiated at 4 wpi (Fig. 1A, protocol 2, and Fig. 1C), and bacterial burdens were measured 3 weeks later. Interestingly, the effects of SnPPiX administration were more prominent in the lungs than in mediastinal lymph nodes or spleens (Fig. 1C).

The pathogen-specific T cell response in lungs of M. {\textit{tuberculosis}}-infected mice is known to be delayed until approximately 3 wpi (11). This suggested to us that the delay in efficacy of SnPPiX on murine M. {\textit{tuberculosis}} infection might be due to a requirement for T lymphocyte cooperation in the activity of the HO-1 inhibitor. To test this hypothesis, we administered SnPPiX to M. {\textit{tuberculosis}}-infected C57BL6/6 (wild type [WT]) and T cell receptor α-deficient (TCR-α−/−) mice (which lack conventional TCR-αβ+ CD4 and CD8 T cells) beginning at 4 weeks postbacterial exposure (Fig. 1A, protocol 2). SnPPiX treatment failed to protect the infected TCR-α−/− mice, which presented similar mortality kinetics as untreated TCR-α−/− mice (Fig. 1D). In parallel experiments in which animals were euthanized at 2 weeks after treatment initiation, SnPPiX-treated infected TCR-α−/− mice displayed bacterial loads indistinguishable from those in untreated TCR-α−/− animals, while WT animals treated with the compound showed a highly significant reduction in mycobacterial burden compared to untreated control mice (Fig. 1E). To control for the higher bacterial burden expected in TCR-α−/− mice at 4 wpi, we performed a separate set of experiments in which we initiated SnPPiX administration on the same day as infection (Fig. 1A, protocol 1) and then evaluated pulmonary bacterial load after 6 weeks of treatment. As expected, WT mice receiving SnPPiX displayed a significant reduction in pulmonary bacterial loads, while among the surviving TCR-α−/− mice no difference in bacterial burden was observed (Fig. 1F). These results indicated that the efficacy of SnPPiX on M. {\textit{tuberculosis}} infection is depen-
dent on host T cells and indirectly argue against a possible direct effect of the inhibitor on the bacteria themselves.

Additional experiments were then performed to formally rule out the possibility that SnPPIX is directly toxic for *M. tuberculosis*, a situation that might occur through its targeting of the bacterium’s own heme-degrading enzyme, MhuD, used by the pathogen for iron acquisition (12). To test this hypothesis, we first cultured bacteria in either iron-containing or iron-free GAST (glycerol-alanine-salts-Tween 80) liquid medium in the presence of increasing concentrations of SnPPIX over a 28-day period. No inhibition of bacterial growth was observed even at 125 μM SnPPIX in complete medium, while toxicity was observed at 125 μM in iron-free medium. This slight attenuation of growth was rescued in the presence of 10 μM hemin, arguing that the attenuation was unre-
lated to the inhibition of MhuD activity by SnPPIX (see Table S1 in the supplemental material).

When exposed to adverse conditions, such as low pH and oxygen concentrations, as well as to reactive oxygen or nitrogen species, *M. tuberculosis* undergoes changes in gene expression and metabolism that promote its survival in the harsh phagosomal environment of activated macrophages (13). In order to test whether such conditions might promote bacterial sensitivity to SnPPIX, we cultured *M. tuberculosis* in low-pH 7TH9 medium in the presence of 100 μM sodium nitrite to simulate both acid and nitrosative stress from the intramacrophage compartment. Even at SnPPIX concentrations as high as 125 μM, no inhibition of bacterial growth was observed over a 21-day period in either the presence or absence of nitrite (see Table S1 in the supplemental material).

We next tested whether SnPPIX could be directly degraded by *M. tuberculosis* MhuD or inhibit its heme-degrading activity. While MhuD-heme complexes underwent rapid degradation, MhuD-SnPPIX complexes remained stable for at least 24 h (see Fig. S1A in the supplemental material), demonstrating that SnPPIX is not cleaved by the bacterial enzyme. Moreover, when MhuD-heme complexes were incubated in the presence of SnPPIX at concentrations as high as 2 μM, no inhibition of heme degradation was observed (see Fig. S1B). In sharp contrast, the heme-degrading activity of mammalian HO-1 was completely blocked under the same conditions (see Fig. S1C). Together, these findings argue that the *in vivo* effects of SnPPIX on *M. tuberculosis* infection are unlikely to be due to a direct effect of the compound on the bacterium itself.

To further explore the requirement for T cells in the activity of SnPPIX on *M. tuberculosis* infection *in vivo*, we next asked whether induction of the host HO-1 is altered in T cell-deficient mice. In lungs of WT mice, increases in HO-1 gene expression were not detected until 3 wpi, and the protein, as measured by Western blotting, was first evident at the same time point (Fig. 1G and H). In TCR-α−/− mice, HO-1 gene and protein expression were delayed until 4 to 5 wpi and were reduced relative to that observed in WT lungs (Fig. 1G and H), despite the increased bacterial loads present in the TCR-α−/− animals (Fig. 1I). In direct contrast, expression of bacterial MhuD mRNA, if anything, was increased in the lungs of infected TCR-α−/− mice (Fig. S1D in the supplemental material), reinforcing the finding that *M. tuberculosis* MhuD is unaffected by SnPPIX and plays no role in the phenomena observed.

Together, the above results suggest that *M. tuberculosis* infection is refractory to SnPPIX treatment in T cell-deficient mice because of reduced pulmonary expression of host HO-1. The latter could result from either impaired recruitment of enzyme-expressing cells to the lungs or defect inductive synthesis of HO-1 because of the absence of a T cell response. In this regard, macrophages and monocytes rather than T cells have been shown to be the major source of HO-1 in infected lungs of WT mice as well as human lungs (14). While purified bone marrow-derived macrophage cultures can produce HO-1 in response to *M. tuberculosis* infection in the absence of T cells (7), it is possible that the infected tissue macrophage subpopulations in the lungs of *M. tuberculosis*-exposed mice require additional T cell activation signals to achieve optimal enzyme expression *in vivo*. Future work is needed to resolve the nature of the T cell requirement in SnPPIX function in order to better inform the use of this strategy as an HDT in TB patients.

We next evaluated whether adjunctive administration of SnPPIX could enhance the efficacy of conventional anti-TB drug therapy. To do so, we treated infected mice at 4 weeks postinfection with either rifampin (R), isoniazid (H), and pyrazinamide (Z) alone (RHZ), SnPPIX alone, or a combination of SnPPIX plus RHZ, and we measured bacterial burdens after 3 weeks or later (Fig. 2A). The RHZ and SnPPIX treatments each resulted in an approximate 1-log reduction in pulmonary bacterial loads below those in untreated infected animals, and when combined these treatments resulted in an additive 2-log reduction in mycobacterial burden (Fig. 2B, left panel). As expected from our earlier experiments, the adjunctive treatment with SnPPIX failed to enhance RHZ efficacy in infected T cell-deficient mice (Fig. 2B, right panel). We then performed a time course experiment to evaluate the long-term consequence of combined SnPPIX-RHZ therapy. Interestingly, the major additive effects of SnPPIX on RHZ treatment were observed during the first 3 weeks of drug administration. Regardless, the combined therapy resulted in undetectable bacterial loads at 17 weeks from initiation of treatment, while mycobacteria were still detected as late as 21 weeks in mice treated with RHZ alone (Fig. 2C). Although effective when administered at the same time as antibiotic treatment, SnPPIX supplementation failed to enhance RHZ efficacy when initiated 6 weeks after the start of drug therapy (see Fig. S2A in the supplemental material). This outcome may have been due to a decline in host HO-1 expression following RHZ administration (see Fig. S2B), which was temporally correlated with both the reduction in bacterial burden and in the magnitude of the accompanying CD4+ (see Fig. S2C) and CD8+ (see Fig. S2D) T cell gamma interferon response at 3 weeks after initiation of RHZ therapy.

**Conclusions.** HO-1 is produced by host cells in response to oxidative stress and catalyzes heme degradation to iron, carbon monoxide (CO), and biliverdin. Bilirubin has potent antioxidant properties, while CO has cytoprotective effects (3). In addition, HO-1, by degrading heme, can suppress the inflammatory tumor necrosis factor-inducing and interleukin-1β (IL-1β)-inducing properties of that molecule (15) and has been shown to promote IL-10-mediated suppression (16). These anti-inflammatory effects can have paradoxical outcomes during the response to infection, as they can be host protective in some settings, such as experimental malaria (17) and Chagas’ disease (18), while detrimental in others, such as experimental melioidosis (19) and macrophage infection with *Leishmania chagasi* (20) or *Salmonella enterica* serovar Typhimurium (21). Such pathogen-promoting effects of HO-1 have been attributed to its suppression of the production of antimicrobial proinflammatory cytokines and metabolites by infected cells.

HO-1 production during *M. tuberculosis* infection was initially argued to be beneficial to the host, since CO released during heme degradation was shown to be toxic to the bacilli and to induce the expression of stress response genes (4, 5, 22). Consistent with these observations, mice with a genetically engineered deletion in the *Hmox1* gene displayed increased susceptibility to *M. tuberculosis* infection (8), although these animals are known to possess major secondary defects that affect the hematopoietic compartment, and they display spontaneous mortality (9, 10).

The results presented here, in which pharmacological blockade of HO-1 resulted in marked reduction in bacterial load, argue
instead for a host-detrimental role for the enzyme in *M. tuberculosis* infection. This conclusion is supported by a recent study demonstrating that pharmacological inhibition of HO-1 in *M. tuberculosis*-infected human macrophages resulted in a reduction in intracellular bacterial loads as well as decreased proinflammatory cytokine production (14). Although we at present cannot rule out possible off-target effects of SnPPIX, our data indicate that direct toxicity of the compound for *M. tuberculosis* itself is highly unlikely. The mechanism(s) by which HO-1 inhibition might suppress pathogen growth is currently unclear. Heme triggers the production of reactive oxygen species (15), which are toxic to *M. tuberculosis* bacilli (23), and therefore, blockade of its degradation by HO-1 may result in higher production of these metabolites and consequently enhanced bacterial killing. Another possibility is that reduced heme degradation resulting from HO-1 inhibition may lead to diminished bacterial growth by limiting the availability of nutritionally required free iron (24).

Regardless of the exact mechanism involved, the data presented here reveal pharmacological inhibition of HO-1 as a candidate strategy for both direct and adjunctive therapy of tuberculosis. HO-1 inhibitors such as SnPPIX have already been used clinically in the treatment of jaundice in infants (25) and thus could potentially be repurposed for use in TB patients. However, further preclinical work is necessary to compare the efficacy of different HO-1 inhibitors, determine their optimal formulation (alone and in combination with conventional antibiotics), and confirm the safety of this new HDT strategy before considering human trials.

**SUPPLEMENTAL MATERIAL**

Supplemental material for this article may be found at [http://mbio.asm.org/lookup/suppl/doi:10.1128/mBio.01675-16/-/DCSupplemental](http://mbio.asm.org/lookup/suppl/doi:10.1128/mBio.01675-16/-/DCSupplemental).

Text S1, PDF file, 0.1 MB.

Table S1, PDF file, 0.04 MB.

Table S2, PDF file, 0.03 MB.

Figure S1, PDF file, 1.7 MB.

Figure S2, PDF file, 2.1 MB.

**ACKNOWLEDGMENTS**

We are grateful to Dan Barber, Katrin Mayer Barber, Dragana Jankovic, and Robert Wilkinson for their helpful advice during the course of this study and to Thomas L. Poulos (University of California Irvine) for generously providing recombinant hHO-1 variant clone G139A.

D.L.C., R.N., E.P.A., K.A., L.M., and A.C. performed the experiments; D.L.C., K.A., M.M., H.B., C.W.G., B.B.A., and A.S. designed the experiments; C.E.B., C.W.G., and A.S. provided materials and infrastructural support; A.S. and C.W.G. mentored the work; D.L.C., B.B.A., and A.S. wrote the manuscript.

This study was funded by the Intramural Research Program of the NIAID; by a fellowship to D.L.C. from the Brazilian National Council of Scientific and Technological Development (CNPq) Science Without Borders Program 237267/2012-8, NIH grant AI095208 (C.W.G.), and National Science Foundation grant NSF-GRFP DGE-1321846 (A.C.).

The funders had no role in study design, data collection and interpre-
tation, or the decision to submit the work for publication. The authors declare no conflict of interests.

**FUNDING INFORMATION**

This work, including the efforts of Diego Luis Costa, was funded by Brazilian National Council of Scientific and Technological Development (CNPq) (237267/2012-8). This work, including the efforts of Celia Goulding, was funded by HHS | National Institutes of Health (NIH) (AI095208). This work, including the efforts of Diego Luis Costa, was funded by HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) (Intramural Research Program). This work, including the efforts of Alex Chao, was funded by National Science Foundation (NSF) (NSF-GRFP DGE-1321846).

**REFERENCES**

1. WHO. 2015. Global tuberculosis report 2015. WHO, Geneva, Switzerland.

2. Hawn TR, Shah JA, Kalman D. 2015. New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics. Immunity 42:544–562. http://dx.doi.org/10.1016/j.immuni.2015.02.007

3. Gozzelino R, Jeney V, Soares MP. 2016. Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol 56:233–254. http://dx.doi.org/10.1146/annurev.pharmtox.010909.105600

4. Shiloh MU, Manzannillo P, Cox JS. 2008. Mycobacterium tuberculosis senses host-derived carbon monoxide during macrophage infection. Cell Host Microbe 3:323–330. http://dx.doi.org/10.1016/j.chom.2008.03.007

5. Kumar A, Deshane JS, Crossman DK, Bolsetty S, Yan BS, Kramnik I, Agarwal A, Steyn AJ. 2008. Heme oxygenase-1-derived carbon monoxide induces the Mycobacterium tuberculosis dormancy regulon. J Biol Chem 283(18):18032–18039. http://dx.doi.org/10.1074/jbc.M802274200

6. Andrade BB, Pavan Kumar N, Mayer-Barber KD, Barber DL, Sridhar R, Rehka VV, Jawahar MS, Nutman TB, Sher A, Babu S. 2013. Plasma heme oxygenase-1 levels distinguish latent or successfully treated human tuberculosis from active disease. PLoS One 8:e62618. http://dx.doi.org/10.1371/journal.pone.0062618

7. Andrade BB, Pavan Kumar N, Amaral EP, Riteau N, Mayer-Barber KD, Tosh KW, Maier N, Conceição EL, Kuhler A, Sridhar R, Banerukha VV, Jawahar MS, Barbosa T, Manganelli VC, Moss J, Fontana JR, Marcano BE, Sampaio EP, Olivier KN, Holland SM, Jackson SH, Moayery M, Leppla S, Sereti I, Barber DL, Nutman TB, Babu S, Sher A. 2015. Heme oxygenase-1 regulation of Matrix metalloproteinase-1 expression underslies distinct disease profiles in tuberculosis. J Immunol 195:2763–2773. http://dx.doi.org/10.4049/jimmunol.1500942

8. Silva-Gomes S, Appelberg R, Larsen R, Soares MP, Gomes MS. 2013. Heme catabolism by heme oxygenase-1 confers host resistance to Mycobacterium infection. Infect Immun 81:2536–2545. http://dx.doi.org/10.1128/IAI.00251-13

9. Fraser ST, Midwinter RG, Coupland LA, Kong S, Berger BS, Yeo JH, Andrade OC, Cromer D, Suarana C, Lam M, Maghazal GJ, Chong BH, Parish CR, Stocker R. 2015. Heme oxygenase-1 deficiency alters erythroblastic island formation, steady-state erythropoiesis and red blood cell lifespan in mice. Haematologica 100:601–610. http://dx.doi.org/10.3324/haematol.2014.116368

10. Kvitunovych G, Eckhaus MA, Ghosh MC, Ollivierrie-Wilson H, Rouault TA. 2010. Dysfunction of the heme recycling system in heme oxygenase-1-deficient mice: effects on macrophage viability and tissue iron distribution. Blood 116:6054–6062. http://dx.doi.org/10.1182/blood-2010-03-272138

11. Wolf AJ, Desvignes I, Linas B, Banaice N, Tamura T, Takatsu K, Ernst JD. 2008. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J Exp Med 205:105–115. http://dx.doi.org/10.1084/jem.20071367

12. Owens CP, Chim N, Goulding CW. 2013. Insights on how the Mycobacterium tuberculosis heme uptake pathway can be used as a drug target. MBio 4(6):e00721-13. http://dx.doi.org/10.1128/mBio.00721-13

13. Russell DG. 2011. Mycobacterium tuberculosis and the innate discourse of a chronic infection. Immunity 24:252–268. http://dx.doi.org/10.1016/j.immuni.2010.09.007

14. Scharn CR, Collins AC, Nair VR, Stamm CE, Marciano DK, Graviss EA, Shiloh MM. 2016. Heme oxygenase-1 regulates inflammation and mycobacterial survival in human macrophages during Mycobacterium tuberculosis infection. J Immunol 196:4641–4649. http://dx.doi.org/10.4049/jimmunol.1500434

15. Dutra FF, Bozza MT. 2014. Heme on innate immunity and inflammation. Front Pharmacol 5:115. http://dx.doi.org/10.3389/fphar.2014.00115

16. Lee TS, Chau LY. 2002. Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat Med 8:240–246. http://dx.doi.org/10.1097/01.nmn.0000016575.01660.4e

17. Pamplona A, Ferreira A, Balla J, Jeney V, Balla G, Epiphanio S, Chora A, Rodrigues CD, Gregoire IP, Cunha-Rodrigues M, Portugal S, Soares MP, Mota MM. 2007. Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria. Nat Med 13:703–710. http://dx.doi.org/10.1038/nm1586

18. Paiva CN, Feijó DF, Dutra FF, Carneiro VC, Freitas GB, Alves LS, Mesquita J, Fortes GB, Figueiredo RT, Souza HS, Fantappié MR, Lannes-Vieira J, Bozza MT. 2012. Oxidative stress fuels Trypanosoma cruzi infection in mice. J Clin Invest 122:2531–2542. http://dx.doi.org/10.1172/JCI51852

19. Stolt C, Schmidt IH, Sayfart Y, Steinmetz I, Bast A. 2016. Heme oxygenase-1 and carbon monoxide promote Burkholderia pseudomallei infection. J Immunol 197:834–846. http://dx.doi.org/10.4049/jimmunol.1403104

20. Lopes NF, Andrade BB, Feijó DF, Araújo-Santos T, Carvalho GQ, Andrade D, Abanades DR, Melo EV, Silva AM, Brodsky CL, Barral-Netto M, Barral A, Soares RP, Almeida RP, Bozza MT, Borges VM. 2012. Heme oxygenase-1 promotes the persistence of Leishmania chagasi infection. J Immunol 188:4460–4467. http://dx.doi.org/10.4049/jimmunol.1103072

21. Mitterstaller AM, Haschka D, Dichtl S, Nairz M, Demetz E, Talarz H, Soares MP, Einwallner E, Estherhauer B, Fang FC, Geley S, Weiss G. 2016. Heme oxygenase 1 controls early innate immune response of macrophages to Salmonella typhimurium infection. Cell Microbiol 18:1374–1389. http://dx.doi.org/10.1111/cmi.12578

22. Zacharia VM, Manzannillo PS, Nair VR, Marciano DK, Kinch LN, Grishin NV, Cox JS, Shiloh MU. 2013. Cor, a novel carbon monoxide resistance gene, is essential for Mycobacterium tuberculosis pathogenesis. mBio 4(6):e00721-13. http://dx.doi.org/10.1128/mBio.00721-13

23. Akaki T, Tomioka H, Shinizu T, Dekio S, Sato K. 2000. Comparative roles of free fatty acids with reactive nitrogen intermediates and reactive oxygen intermediates in expression of the iai activity of macrophages against Mycobacterium tuberculosis. Clin Exp Immunol 121:302–310. http://dx.doi.org/10.1046/j.1365-2249.2000.01298.x

24. Fang Z, Sampson SL, Warren RM, Gey van Pittius NC, Newton-Foot M. 2015. Iron acquisition strategies in mycobacteria. Tuberculosis (Edinb) 95:123–130. http://dx.doi.org/10.1016/j.tube.2015.01.004

25. Kappas A, Drummond GS, Manola T, Petmezaki S, Vales A. 1988. Sn-protoporphyrin use in the management of hyperbilirubinemia in term newborns with direct Coombs-positive ABO incompatibility. Pediatrics 81:485–497.